• Explore /
  • Poster
  • / A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: An Eastern Cooperative Oncology Group study (E2511).

A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: An Eastern Cooperative Oncology Group study (E2511).

Abstract Poster

Authors

Taofeek Owonikoko

Taofeek Kunle Owonikoko

The Winship Cancer Institute of Emory University, Atlanta, GA

Taofeek Kunle Owonikoko , Suzanne Eleanor Dahlberg , Saad A. Khan , David E. Gerber , Jonathan Dowell , Rebecca Anne Moss , Chandra Prakash Belani , Christine L. Hann , Charu Aggarwal , Suresh S. Ramalingam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01642251

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 7523)

DOI

10.1200/jco.2014.32.15_suppl.7523

Abstract #

7523

Poster Bd #

16

Abstract Disclosures

Similar Posters

First Author: Daniel E. Castellano

First Author: Arjun Mittra

First Author: Albert Font Pous

First Author: Daniel E. Castellano